Novel thrombopoietic agents: A new era for management of patients with thrombocytopenia

Haematologica

Volumn 93, Issue 10, 2008, Pages 1445-1449

  George, James N ^a   Terrell, Deirdra R ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AKR 501; BUTYZAMIDE; DEXAMETHASONE; ELTROMBOPAG; FIBRINOLYTIC AGENT; GLUCOCORTICOID; IMMUNOGLOBULIN; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN F(AB) FRAGMENT 59; LGD 4665; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MA 01G4G344; MONOCLONAL ANTIBODY VB22B SC (FV)2; PEGYLATED RECOMBINANT MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR; PEGYLATED THROMBOPOIETIN; PEPTIDE DERIVATIVE; PLACEBO; RECOMBINANT MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR; RECOMBINANT THROMBOPOIETIN; REMIPLISTIM; RHESUS D ANTIBODY; RITUXIMAB; THROMBOPOIETIN; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ACUTE GRANULOCYTIC LEUKEMIA; APHERESIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; CLINICAL TRIAL; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDITORIAL; HEMATOLOGIC MALIGNANCY; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; LOW DRUG DOSE; PATHOGENESIS; QUALITY OF LIFE; SIDE EFFECT; SINGLE DRUG DOSE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOCYTOPOIESIS; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

BLOOD PLATELETS; DRUG EVALUATION, PRECLINICAL; HUMANS; PHARMACEUTICAL PREPARATIONS; THROMBOCYTOPENIA; THROMBOPOIESIS;

EID: 54349126159     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.13725     Document Type: Editorial

References (19)

1. Kuter DJ. New thrombopoietic growth factors. Blood 2007;109:4607-16.
2. Bussel JB, Kuter DJ, George JN, McMillan R, Aledort LM, Conklin GT, et al. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. New Eng J Med 2006;355:1672-81.
3. Bussel JB, Cheng G, Saleh MN, Psaila B, Kovaleva L, Meddeb B, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007;357:2237-47.
4. Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomized controlled trial. Lancet 2008;371:395-403.
5. Nogami W, Yoshida H, Koizumi K, Yamada H, Abe K, Arimura A, et al. The effect of a novel, small non-peptidyl molecule butyzamide on human thrombopoietin receptor and megakaryopoiesis. Haematologica 2008;93:1495-504.
6. Segal JB, Powe NR. Prevalence of immune thrombocytopenia: analysis of administrative data. J Thromb Haemost 2006;4:2377-83.
7. George JN. Management of patients with refractory immune thrombocytopenic purpura. J Thromb Haemost 2006;4:1664-72.
8. Harrington WJ, Minnich V, Hollingsworth JW, Moore CV. Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura. J Lab Clin Med 1951;38:1-10.
9. Shulman NR, Weinrach RS, Libre EP, Andrews HL. The role of the reticuloendothelial system in the pathogenesis of idiopathic thrombocytopenic purpura. Trans Assoc Amer Phys 1965;78:374-390.
10. Ballem PJ, Segal GM, Stratton JR, Gernsheimer T, Adamson JW, Slichter SJ. Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenia purpura. Evidence for both impaired platelet production and increased platelet clearance. J Clin Invest 1987;80:33-40.
11. Emmons RVB, Reid DM, Cohen RL, Meng G, Young NS, Dunbar CE, et al. Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction. Blood 1996;87:4068-71.
12. Vesely SK, Perdue JJ, Rizvi MA, Terrell DR, George JN. Management of adult patients with idiopathic thrombocytopenic purpura after failure of splenectomy. A systematic review. Ann Int Med 2004;140:112-20.
13. Mathias SD, Bussel JB, George JN, McMillan R, Okano GJ, Nichol JL. A disease-specific measure of health-related quality of life in adults with chronic immune thrombocytopenic purpura: psychometric testing in an open-label clinical trial. Clin Ther 2007;29:950-7.
14. Kojouri K, Vesely SK, Terrell DR, George JN. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic literature review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood 2004;104:2623-34.
15. Arnold DM, Dentali F, Crowther MA, Meyer RM, Cook RJ, Sigouin C, et al. Systematic review: Efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Int Med 2007;146:25-33.
16. Imbach P, Kühne T, Müller D, Berchtold W, Zimmerman S, Elalfy M, et al. Childhood ITP: 12 months follow-up data from the prospective registry I of the intercontinental childhood ITP study group (ICIS). Pediatr Blood Cancer 2006;46:351-6.
17. McHutchison JG, Dusheiko G, Shiffman ML, Rodriguez-Torres M, Sigal S, Bourliere M, et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. TPL102357 Study Group. N Engl J Med 2007;357:2227-36.
18. Douglas VK, Tallman MS, Cripe LD, Peterson LC. Thrombopoietin administered during induction chemotherapy to patients with acute myeloid leukemia induces transient morphologic changes that may resemble chronic myeloproliferative disorders. Amer J Clin Path 2002;117:844-50.
19. Kantarjian HM, Fenaux P, Sekeres MA et al. Phase 1/2 study of AMG 531 in thrombocytopenic patients with low-risk myelodysplastic syndrome: update including extended treatment. Blood 2007;110:81a[abstract.]